Theraclone Sciences, Inc. Announces Positive Top-Line Data From Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection
4/2/2013 9:44:11 AM
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-202, which was discovered using Theraclone’s I-STARTM platform. TCN-202 is a broadly protective, fully human monoclonal antibody, being developed for the treatment of human cytomegalovirus (CMV) infection. TCN-202 was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed, and demonstrated a favorable immunogenicity profile.
comments powered by